Problems with FIB-4 as an initial screening tool for liver fibrosis in patients with type 2 diabetes

References

[1] Khan MAB,Hashim MJ,King JK,Govender RD,Mustafa H,Al Kaabi J. Epidemiology of type 2 diabetes - global burden of disease and forecasted trends J Epidemiol Glob Health 2020 10 107 11 PMC7310804

[2] En Li Cho E,Ang CZ,Quek J.et al. Global prevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus: an updated systematic review and meta-analysis Gut 2023 72 2138 48

[3] Cusi K,Abdelmalek MF,Apovian CM.et al. Metabolic dysfunction-associated steatotic liver disease (MASLD) in people with diabetes: the need for screening and early intervention. a consensus report of the american diabetes association Diabetes Care 2025 48 1057 82

[4] Rinella ME,Neuschwander-Tetri BA,Siddiqui MS.et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease Hepatology 2023 77 1797 835 PMC10735173

[5] European Association for the Study of the Liver. EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update J Hepatol 2021 75 659 89

[6] European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease J Hepatol 2016 64 1388 402

[7] Kanwal F,Shubrook JH,Adams LA.et al. Clinical care pathway for the risk stratification and management of patients with nonalcoholic fatty liver disease Gastroenterology 2021 161 1657 69 PMC8819923

[8] ElSayed NA,Aleppo G,Aroda VR.et al. 4. comprehensive medical evaluation and assessment of comorbidities: standards of care in diabetes-2023 Diabetes Care 2023 46 S49 67 PMC9810472

[9] Wattacheril JJ,Abdelmalek MF,Lim JK,Sanyal AJ. AGA Clinical Practice update on the role of noninvasive biomarkers in the evaluation and management of nonalcoholic fatty liver disease: expert review Gastroenterology 2023 165 1080 8

[10] Sterling RK,Lissen E,Clumeck N.et al. ; APRICOT Clinical Investigators. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection Hepatology 2006 43 1317 25

[11] Xiao G,Zhu S,Xiao X,Yan L,Yang J,Wu G. Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease: a meta-analysis Hepatology 2017 66 1486 501

[12] Alkayyali T,Qutranji L,Kaya E,Bakir A,Yilmaz Y. Clinical utility of noninvasive scores in assessing advanced hepatic fibrosis in patients with type 2 diabetes mellitus: a study in biopsy-proven non-alcoholic fatty liver disease Acta Diabetol 2020 57 613 8

[13] Mózes FE,Lee JA,Selvaraj EA.et al. ; LITMUS Investigators. Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis Gut 2022 71 1006 19 PMC8995830

[14] Younossi ZM,Paik JM,Henry L,Pollock RF,Stepanova M,Nader F. Economic evaluation of non-invasive test pathways for high-risk metabolic dysfunction-associated steatotic liver disease (MASLD) in the United Kingdom (UK) Ann Hepatol 2025 30 101789

[15] Vilar-Gomez E,Lou Z,Kong N,Vuppalanchi R,Imperiale TF,Chalasani N. Cost effectiveness of different strategies for detecting cirrhosis in patients with nonalcoholic fatty liver disease based on United States Health Care System Clin Gastroenterol Hepatol 2020 18 2305 14.e12

[16] Davyduke T,Tandon P,Al-Karaghouli M,Abraldes JG,Ma MM. Impact of implementing a “FIB-4 First” strategy on a pathway for patients with NAFLD referred from primary care Hepatol Commun 2019 3 1322 33 PMC6771169

[17] Viganò M,Pugliese N,Cerini F.et al. Accuracy of FIB-4 to detect elevated liver stiffness measurements in patients with non-alcoholic fatty liver disease: a cross-sectional study in referral centers Int J Mol Sci 2022 23 12489 PMC9604259

[18] Bhuvanesswar KC,Srivastava BK,Amutha A.et al. Prevalence of hepatic steatosis and fibrosis in Asian Indian individuals with type 2 diabetes Diabetes Ther 2025 16 1797 811 PMC12399469

[19] Mantovani A,Lombardi R,Dalbeni A.et al. Two-tier screening approach for liver fibrosis stratification in outpatients with type 2 diabetes mellitus: a multicenter cross-sectional study Diabetes Obes Metab 2026 28 644 53

[20] Caviglia GP,Ferro A,D’Ambrosio R.et al. Effectiveness of a model of care based on fibrosis-4 and liver stiffness measurement for the screening of patients with type 2 diabetes mellitus at risk of advanced liver disease: results from an Italian prospective multicenter study Am J Gastroenterol 2026 121 375 82

[21] Shaheen AA,Baguley E,Swain MG.et al. Diabetes and obesity reduce FIB-4 accuracy in MASLD referral pathways JHEP Rep 2026 8 101735 PMC12969413

[22] Heyens LJM,van Malde DPA,Dogay Us G.et al. ; MASLD research group. Is FIB-4 the right tool for screening for liver fibrosis? Ann Hepatol 2025;31:102176

[23] Makker J,Tariq H,Kumar K.et al. Prevalence of advanced liver fibrosis and steatosis in type-2 diabetics with normal transaminases: a prospective cohort study World J Gastroenterol 2021 27 523 33 PMC7896434

[24] Yeo YH,Ho HJ,Huang TW.et al. Dynamic FIB-4 score changes and HCC risk in patients with MASLD and elevated liver enzymes: a nationwide cohort study Liver Cancer 2026 Epub ahead of print PMC12931954

[25] Zhou XD,Li YT,Kim SU.et al. ; VCTE-Prognosis Study Group, Paired Liver Biopsy Group. Longitudinal changes in fibrosis markers: monitoring stiffness/fibrosis progression and prognostic outcomes in MASLD Clin Gastroenterol Hepatol 2026 24 394 406

[26] Anstee QM,Berentzen TL,Nitze LM.et al. Prognostic utility of fibrosis-4 index for risk of subsequent liver and cardiovascular events, and all-cause mortality in individuals with obesity and/or type 2 diabetes: a longitudinal cohort study Lancet Reg Health Eur 2024 36 100780 PMC10769893

[27] Schreiner AD,Zhang J,Moran WP.et al. FIB-4 as a time-varying covariate and its association with severe liver disease in primary care: a time-dependent cox regression analysis J Clin Gastroenterol 2024 58 917 22 PMC11096263

[28] Hagström H,Talbäck M,Andreasson A,Walldius G,Hammar N. Repeated FIB-4 measurements can help identify individuals at risk of severe liver disease J Hepatol 2020 73 1023 9

[29] Noureddin M,Jones C,Alkhouri N,Gomez EV,Dieterich DT,Rinella ME. NASHNET Screening for nonalcoholic fatty liver disease in persons with type 2 diabetes in the United States is cost-effective: a comprehensive cost-utility analysis Gastroenterology 2020 159 1985 7.e4

[30] van Kleef LA,Francque SM,Prieto-Ortiz JE.et al. Metabolic dysfunction-associated fibrosis 5 (MAF-5) score predicts liver fibrosis risk and outcome in the general population with metabolic dysfunction Gastroenterology 2024 167 357 67.e9

[31] Kim J,Ito T,Arai T.et al. Modified FIB-4 index in type 2 diabetes mellitus with steatosis: a non-linear predictive model for advanced hepatic fibrosis Diagnostics 2024 14 2500 PMC11592587

[32] Kjaergaard M,Lindvig KP,Thorhauge KH.et al. Using the ELF test, FIB-4 and NAFLD fibrosis score to screen the population for liver disease J Hepatol 2023 79 277 86

[33] Buchanan R,Reinson T,Bilson J.et al. OS-030 A multicentre randomised controlled trial of screening for MASLD in patients with type 2 diabetes not known to have liver disease in primary care J Hepatol 2026 84 S25 6